AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Bright Minds Biosciences Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Z61F382
52.48▼ 0.21 (-0.40%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
52.69
Day's Range
51.00 – 52.65
52-Week Range
47.23 – 124.24
Volume
57.1K
Avg Volume
133.3K
Share Statistics
Shares Outstanding
Employees
25
Exchange
XNAS
Listed
2021-03-08
Share count as of September 30, 2025

Bright Minds Biosciences Inc. Common Stock (DRUG) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Bright Minds Biosciences Inc. Common Stock (DRUG)
What is Bright Minds Biosciences Inc. Common Stock's Market Cap?
Bright Minds Biosciences Inc. Common Stock's Market Cap is $400.7M, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Enterprise Value?
Bright Minds Biosciences Inc. Common Stock's Enterprise Value is $340.9M, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Net Income (TTM)?
Bright Minds Biosciences Inc. Common Stock's Net Income (TTM) is -$8.8M, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Diluted EPS (TTM)?
Bright Minds Biosciences Inc. Common Stock's Diluted EPS (TTM) is -1.16, based on as-reported figures from SEC (XBRL) filings.
What is Bright Minds Biosciences Inc. Common Stock's Net Debt?
Bright Minds Biosciences Inc. Common Stock's Net Debt is -$59.8M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · DRUGAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of CAD, except per-share data)
Source: Akyla.ai
Line ItemSep 30, 2025Sep 30, 2024Sep 30, 2023Sep 30, 2022Sep 30, 2021Sep 30, 2020
EXPENSES
Consulting fees
Directors’ compensation
Foreign exchange
Marketing, advertising, and investor relations
Office and administrative
Professional fees
Regulatory and filing
Research and development
Loss before other items
Other items
Interest income
Net and comprehensive loss
Basic and diluted loss per share (in CAD per share)